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INTRODUCTION 
 
 
The magnitude of breast cancer in the United States and the human costs it regularly 
claims is disconcerting. Breast cancer is the second leading cause of death from cancer in 
American women.1 My personal relationship with this subject matter is limited to first-hand 
observation. By virtue of my grandmother, Leni, who battled what began as a diagnosis of breast 
cancer turned to a decade long fight with metastatic cancer, I gained a sense of what it meant to 
be a caregiver. Leni displayed the true grit of an Albanian woman who was in reality, ill-
equipped to take on the American healthcare system. In a medical landscape where healthcare 
providers have a stronghold on decision-making, it was clear that her autonomy would be 
compromised by a cultural barrier to communication. Her dominant language was Albanian, and 
she understood only a handful of words in English. Under these circumstances, her interactions 
with health professionals and support staff were mediated by my mother’s translations which she 
often communicated piecemeal back to my grandma. In recognizing Leni’s culturally-ingrained 
phobia of cancer, my mother was also careful to omit any language that hinted at her terminal 
diagnosis.  
Leni spoke about the employees who engaged with her during chemotherapy sessions or 
visits to her oncologist with great enthusiasm. Their interactions were not traditional in the 
linguistic sense; she opted to receive and relay emotions through touch. Employees met her smile 
by gently resting their hand on her back, reassuring her that she was in competent care. Their 
spirit traveled back to her one-bedroom apartment which she adorned with the flushed pink roses 
given to her by the office clerk. Following each medical visit to Saint Vincent’s Center for 
Cancer Care, patients are given a rose to commend their resilience during their separately long 
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and arduous journeys. The symbolic significance of the rose may be interpreted in one of two 
ways depending on one’s individual worldview. An optimistic outlook would reckon that each 
rose represent a mile successfully and valiantly completed by a patient training for their cancer 
treatment marathon. A less agreeable outlook would consider the rose a mark of an ephemeral 
existence. The fleeting nature of existence manifests over time as the petals become discolored 
and the rose hangs limply on its stem. With each medical visit, patients’ bodies bear the brunt of 
cytotoxic drugs and other therapies. Although a patient may be well-informed of the end-goals of 
their treatment, they may not necessarily be prepared to experience the initial force of 
depreciating health caused by their intensive treatment.  
I found myself wallowing in a pool of angst, not only frightened by my lack of control 
over the situation but my incapacity to identify with my grandma’s internal turmoil. I was 
unsettled by the level of faith she vested in her providers. Rarely did she pause to consider the 
risks associated with getting treatment or the chances that it would not fully rid her body of the 
cancer. She dove in – head-first. Yes, my grandma had always been a woman of strong-will. But 
in this period of her life, she seemed to blindly express agreement with anyone who was 
responsible for her well-being. Cognizant of my own experiential limitations, this tension 
inspired me to embark on a scholarly journey to understand my grandmother’s unique 
experiences as an immigrant woman navigating her personal health and wellness. Amidst a 
convoluted healthcare system and a shortage of social change, I attempt to reclaim control over 
our collective understanding of the provision of breast health services. Since screening is 
currently the gateway to the detection and subsequent treatment of breast cancer, it will be the 
primary focus of this thesis and the basis for creating best practices guidelines to meet women’s 
unique health needs.  
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Breast cancer screening is a standard of care in the United States; it is widely believed to 
help asymptomatic women achieve earlier diagnosis and improve their likelihood of survival. In 
the interest of being consistent with the majority of literature published on this topic, “woman” is 
used to refer to individuals assigned biologically female at birth. This is not to negate the 
existence of breast cancer among men and genderqueer/non-binary/transgender individuals. In 
this thesis, I strive to characterize the diverse experiences of women who get breast cancer 
screening or are eligible for screening. A large proportion of women attend imaging centers to 
get annual or biennial screening. These are the hubs where patients come into contact with 
service and support staff who may shape the trajectory of their mammography experience. Lest 
we forget, these experiences are embedded in and inextricably tied to the broader use of medical 
technology and the organization of healthcare in the United States. Hence, focusing on screening 
as an isolated process will ultimately prove futile given its intersections with broader systemic 
behaviors and structural forces in the healthcare industry.  
 To cultivate a holistic understanding of the ecology in which the delivery of breast cancer 
screening services take place, the following chapters are organized around the concept of the 
clinical microsystem. The microsystem typifies a small unit of the larger healthcare organization. 
In this thesis, the clinical microsystem of a breast imaging center will be used as a conceptual 
model to illustrate the domains of screening. At a breast imaging center, clinicians and staff are 
working interdependently for a shared purpose to screen, educate and support women. Studies 
have shown that the care and outcomes delivered by our healthcare systems hinge on productive 
exchanges in the workplace between all incoming and outgoing actors. This includes interactions 
between healthcare professionals, support staff, patients as well as the technology operated in the 
clinic. Out of this web of relationships emerges a larger trend in patient outcomes.  
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In order to build a biological and historical framework, I begin by examining the ways 
that science and the field of radiology have been foundational parts of breast cancer screening. 
Chapter 1 delineates the biological, behavioral and underlying social factors that are associated 
with an increased risk of acquiring breast cancer. Understanding the pathogenesis and 
epidemiology of the disease will become the basis for developing any sort of targeted solution 
involving the microsystem, as discussed in later chapters. Additionally, Chapter 1 provides 
insight into the institutional underpinnings of radiology and how doctors have had to sacrifice 
“visibility” for productivity in managing high imaging volumes.  
Screening examinations help women achieve early diagnosis. Mammography, a non-
invasive imaging tool that utilizes low-dose x-ray, has been considered the gold standard for the 
early detection of breast cancer.2 Although the mammography is rarely condemned in public, its 
shortcomings are well noted in research literature. High rates of false positive tests have 
contributed to the relatively high recall rates that exist in the U.S. The sensitivity of 
mammography also fares poorly among women with dense breasts.3,4 Overdiagnosis of women 
with ductal carcinoma in situ (DCIS) has been an additional hotly contested topic.  
The perceptions, attitudes and knowledge of patients undergoing screening 
mammography are documented in Chapter 3. A woman’s decision to initially get a mammogram 
and subsequently adhere to screening is contingent on a variety of factors including her 
expectations and prior experiences getting a mammogram as well as her deeply-rooted personal 
values. A synthesis of relevant research on women’s experiences of mammography yielded 
several prominent themes. Many women felt fearful during their visit which was heightened by 
the long waiting period to receive their screening results. The pain and discomfort experienced 
during a visit were also determining factors in follow-up compliance. Upholding a patient’s 
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autonomy in the decision-making process is equally as important, and calls for efforts to fully 
inform patients of the effects of ionizing radiation and breast density legislation. 
The characteristics of high-performing microsystems are outlined in Chapter 4. Often 
times, current care may fall short of achieving an ideal version of care due to gaps in knowledge, 
poor clinical decision-making, unsafe transitions of care or ineffective teamwork.5 Researchers 
have postulated how these breaches in performance may be “attributed to the way our clinical 
teams are organized and how they function and relate in the context of the larger healthcare 
organization.”5 This chapter discusses how clinical units can be leveraged to optimize the quality 
and safety of how we deliver breast cancer screening. According to literature, high performing 
microsystems demonstrate the following eight qualities: integration of information, alignment of 
role and training, measurement, interdependence of the care team, supportiveness of the larger 
system, connection to the community, constancy of purpose, and investment in improvement.6 
The clinical microsystem assessment tool will be used as an apparatus to engage breast cancer 
imaging teams in the process of clinical redesign. 
The final chapter pushes a new agenda among healthcare professionals referred to as the 
personalized risk-based approach. This approach delivers differential services to women based 
on an assessment of their risks and affirming dialogue between them and their provider 
(technician, radiologist or primary care physician). In finding a delicate balance between 
achieving welfare gains for underserved female populations as well as profit seeking aims, a 
personalized risk-based approach can surmount many of the outstanding issues with screening. It 
combines various practices and imaging techniques that purportedly maximize specificity and 
sensitivity while minimizing cost and radiation exposure.7  
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CHAPTER 1: BACKGROUND 
 
 
Pathogenesis and Epidemiology 
 
Breast tissue may develop abnormalities which are sometimes deemed cancerous. Breast 
cancer forms in the breast tissue, particularly in the ducts (tubes that pass milk from the lobules 
to the nipple) and lobules (glands that make milk). A lump in the breast may indicate a growth of 
normal cells, cancer cells, or atypical cells which is the intermediate between them. Cancer cells 
divide uncontrollably and can spread into nearby tissues. If cells stay within the milk ducts or 
lobules it is considered non-invasive, also termed in situ masses. Many in situ masses will 
resolve on their own and/or not progress to invasive cancers. If the cancer has spread beyond the 
membranes of the mammary gland (ducts and lobules), into surrounding tissue, then it is called 
invasive. It may migrate beyond the breast by passing through the blood or lymph system. This 
condition is referred to as metastatic breast cancer.1  
Cancer cells are differentiated from normal cells by their appearance in distinct grades. 
Grade 1 would indicate a low grade; cancer cells look mildly different from normal cells and are 
slow-growing. Grade 2 suggests cells that look different from normal cells; they grow slightly 
faster than normal cells. Grade 3 refers to cells that look very different from normal cells; they 
grow very fast.1  
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Breast cancer is the second leading cause of death from cancer in American women, 
trailing lung cancer. About one woman in eight women (~12.4%) will be diagnosed with the 
invasive form of the disease over the course of her lifetime. In 2018, “an estimated 266,120 new 
cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 
63,960 new cases of non-invasive (in situ) breast cancer.”1 In 2018, 2,550 new cases of invasive 
breast cancer are expected to be diagnosed in men.1 Although this may occur in both women and 
men, a man’s lifetime risk of breast cancer is lower at 1 in 1,000. Breast cancer incidence rates in 
the U.S. have been decreasing since 2000, concluding a two-decade period of rapid growth in 
breast cancer cases. The declining use of hormone replacement therapy (HRT) is hypothesized to 
have contributed to these decreasing rates.8  
Figure 1. Anatomy of the female breast (Breastcancer.org 2016). 
Figure 2. Visual comparison of a non-invasive cell and invasive cell (Breastcancer.org 2016). 
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African-American women demonstrate higher rates of mortality from metastatic breast 
cancer than women of other race/ethnicities in the United States. The occurrence of breast cancer 
is more common in non-Hispanic Black women (NHB) under 45 years of age, relative to non-
Hispanic White women (NHW). For Asian, Hispanic, and Native-American women, the life-
time risk of developing and dying from breast cancer is lower. Between 1975 to 2013, the 5-year 
cause-specific survival of NHW women for metastatic breast cancer was (19-37%) higher as 
compared to other racial ethnic groups, especially NHB (16-26%). Some of the variables that 
account for the racial disparity between NHB and NHW, adjusting for age, include 
socioeconomic factors followed by tumor characteristics and finally metastatic pattern. African-
American women are subsequently more likely to be diagnosed with advanced breast cancer 
characterized by high-grade tumors.9    
A woman’s risk increases with the following factors: age, a personal or family history of 
the disease, a known BRCA1 or BRCA2 gene mutation, beginning menstruation at an early age, 
older age at birth of first child or never having given birth, breast tissue that is dense, use of 
hormones such as estrogen and progesterone, obesity, and consumption of alcoholic beverages. 
A woman is also at high risk if they’ve identified a first-degree relative with a BRCA1 or BRCA2 
gene mutation. She similarly qualifies as high-risk if a risk assessment tool measures her lifetime 
risk of breast cancer at about 20 to 25 percent or greater. Other risk factors include having 
radiation therapy to the chest when they were between the ages of 10 and 30 years, a genetic 
disease such as Li-Fraumeni syndrome, Cowden syndrome, or hereditary diffuse gastric cancer, 
or having a first-degree relative with one of these diseases.10  
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Breast Imaging Center: Service and Support Staff  
 
Breast imaging centers support the philosophy of using opportunistic screening as a vital 
prevention strategy for women who are at average or high risk for breast cancer. Service and 
support staff at a breast imaging center typically include front desk receptionists, technicians, 
and breast radiologists. The front desk clerk is the first point of contact for patients visiting the 
medical office as well as the gatekeeper facilitating the patient’s entry and continuous care. 
Patients are then handed off to the radiologic technologist or radiologic technician under whose 
custody they are for the bulk of the appointment. The technician’s main responsibility is to 
operate the mammography machine to produce digital images. They position the patient’s breast 
on the mammography unit and compress it with a clear plastic paddle in order to visualize the 
breast effectively. Certainly, the intimate nature of this interaction necessitates that technicians 
assume a comforting presence, helping to alleviate any anxiety felt by the patient. The 
examination process takes about 30 minutes and concludes after the radiologist deems the 
images suitable.  
The breast radiologist analyzes the mammography images upon which they may report 
the results to the patient’s primary care or referring physician. The referring provider may 
discuss the results of the mammogram, otherwise, most screening facilities will directly contact 
the patients to notify them of their results. Sometimes the radiologist will be entrusted with the 
task of specifically discussing an abnormal mammogram with the patient and her family.11 Over 
the years, radiologists have established good rapport with other providers. Dubbed the ‘voice of 
reason’ among their colleagues, radiologists have the upper hand when it comes to decisions like 
whether or not to request follow-up exams or long-term monitoring upon discovery of an 
abnormality in the images.10   
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Administrative and clerical staff play a pivotal role in ensuring women have access to 
high quality services. A detailed description of their job expectations in the UK is available 
online through the National Health Service (NHS) Breast Screening Programme. Given the 
thoroughness of this data, I will be using UK performance standards for administrative and 
clerical staff to achieve a baseline understanding of their roles in the U.S. The operations within 
a breast screening office can easily become destabilized without up-to-date, reliable computer 
systems and more importantly, motivated and skillful employees. Staff are primarily responsible 
for ensuring timely and accurate exchange of information between the screening office (SO) and 
health authority (HA). In the UK, health authorities are local level officials and serve as a direct 
link between the Department of Health and the NHS. Staff also facilitate communication 
between the general practitioner (GP), primary health care team (PHCT), and the SO. They 
ensure that GPs and PHCTs are effectively promoting breast screening among their patients. 
Correspondence with patients is also maintained via written letters, telephone and face-to-face 
communication. Women eligible for screening are sent invitations on a regular basis and are 
communicated their results following their visit. They are also provided accurate and up-to-date 
literature informing them about the screening process.12 
 
Radiologists: Evolution Through Time 
 
When radiologists entered the scene in the late 1800s after the discovery of the x-ray, 
they came from wide-ranging professional backgrounds. Unlike modern day health experts, these 
radiologists were not necessarily board-certified MDs. Yet, relative to their present-day 
counterparts, their responsibilities were significantly more comprehensive. Radiologists 
performed the patient’s imaging examination in addition to interpreting the acquired image. The 
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radiologist would then communicate the findings directly to their patient and give them the 
option to keep the images. Decades later, a bureaucratic operation to legitimize the field of 
radiology changed workflow and patient-provider relations. Images were no longer a free 
souvenir nor a commodity to be purchased, they became the property of the medical office. 
Medical offices emphasized that patients were not being charged for their images, but rather for 
the one-on-one consultations they had with the radiologist. On the suggestion of the American 
Roentgen Ray Society in 1916, radiologists began exclusively consulting referring physicians 
with image results. As a final attempt to “enhance professional prestige,” radiologists specialized 
in the lucrative craft of interpreting images while technicians were hired to fill in the remaining 
gaps.13   
An adversarial healthcare system with hospitals and radiologists struggling to act in their 
own self-interest resulted in the contemporary manifestation of the ‘Invisible Radiologist.’  
Rather than investing in private practice resources, circa 1930s, radiologists were galvanized to 
join hospitals that enjoyed a vast expanse of up-to-date equipment. Yet after being haphazardly 
placed in various hospital departments, they received minimal recognition for their work. As the 
lone radiologist in a section of surgery or cardiology, the radiologist was not only overshadowed 
but also under the jurisdiction of other providers in that department. Radiologists were further 
displaced from a position of visibility as hospitals prohibited them from billing for imaging 
services. The 1960s, however, brought a wave of technologic innovation and more formal 
radiologic training. Radiologists transformed into more marketable entities, eventually 
contributing to their own commoditization. In 1965, the Medicare bill finally gave radiologists 
the legitimacy to bill patients for their medical services. Despite increasing demand for 
radiologic procedures, radiologists continued to abide by traditional customs of not 
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communicating with patients. Academic departments also failed to facilitate training programs to 
push forward a new standard of patient interaction. To this day, radiologists’ offices are relegated 
to the background, isolated from the clinic and the patients that they serve.13 
Although radiologists specializing in breast imaging have made significant progress in 
constructing a path towards visibility, they still pale in comparison to most long-term providers. 
Radiologists almost exclusively step out from behind the curtain when having to disclose an 
abnormal finding to a patient. As a result, their presence has tragically become a forewarning of 
illness.14 A survey conducted between 2006 – 2007 shows that 77% of providers often or always 
communicated the abnormal results of diagnostic mammographic examinations to their patients. 
Yet, less than 47.3% communicated the normal results of diagnostic examinations.13 The upside 
is that radiologists have presumably by this point mastered the art of responding to sorrow and 
anxiety.14 The gloomy backdrop of their limited interactions with patients, however, may have 
also unintendedly weakened their bond with patients. Pathologists are similarly positioned at the 
bottom of the medical hierarchy in terms of patient contact. Automation has made their work 
more technologically intensive and as a result, commodified the fruit of their labor. Unlike 
pathology tests, the imaging services offered by radiologists are not solely differentiated by 
price. Radiologists have the opportunity to market themselves as indispensable members of the 
healthcare team, drawing on their expertise to offer personalized services that fit each patient’s 
individual health care needs.15 The American College of Radiology (ACR) proposes this as an 
initial first step towards becoming a more visible member of a patient’s healthcare team. This 
step also subscribes to the ACR’s long-term goal of having radiologists directly communicate the 
results of imaging tests to patients.16 
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CHAPTER 2: BREAST CANCER SCREENING 
 
 
Routine breast cancer screening is conducted with the objective of improving timely 
detection of an invasive cancer so that it may be treated effectively. Breasts are commonly 
examined through physical examinations and mammography, while laboratory and genetic tests 
also exist to detect risk-related mutations. Individuals are offered one or more tests based on a 
medical assessment of their risk factors.17 Though physical examinations can discover breast 
lumps, they are diagnosed as benign 80% of the time. Cysts are characterized as fluid-filled 
benign lumps and are usually found in women under 40. They feel smooth or round. 
Fibroadenomas, noncancerous breast tumors, mostly affect women in their 20s and 30s, are 
benign, and have a smooth and firm or rubbery texture. Cancerous lumps, on the other hand, are 
irregular in shape and they may feel firm and fixed to the breast tissue.18  
 
Mammography 
 
A mammography screening exam, referred to as a mammogram, can help physicians with 
the early detection and diagnosis of breast diseases. It is a non-invasive medical imaging tool that 
utilizes low-dose x-ray to produce pictures of breast tissue. Screening mammography can detect 
breast cancers up to two years prior to the disease physically manifesting itself. Patients who 
may have demonstrated symptoms or obtained abnormal results from their screening 
mammogram may be recommended for diagnostic screening. If a doctor prescribes a diagnostic 
mammogram, multiple x-rays will be taken to offer a view of the breast from multiple vantage 
points. A spectrum of women visibly reap the benefits of imaging: women who are relatively 
symptom-free as well as women with symptoms such as a lump, pain, skin dimpling or nipple 
discharge.10 This thesis, however, will hone in on understanding the process of routine screening 
  
14 
and refrain from further investigation of the diagnostic test that may be hypothetically 
administered afterwards.  
Mammography has been considered the gold standard for early detection of breast 
cancer.2 Its effects have been studied in randomized trials which reveal 15 to 25% reductions in 
mortality rates associated to breast cancer, whereas meta-analyses of observational studies show 
13 to 17% reductions in mortality rates.19 Using this breast imaging technique, radiologists can 
detect small tumors like ductal carcinoma in situ (DCIS) early before they can cause harm to the 
patient. DCIS describes small abnormal tissue growths in the milk ducts in the breast. Screening 
mammography can also detect invasive ductal and invasive lobular cancer which are conditions 
where the cancer has spread to the surrounding breast tissues. While robust concerns about 
radiation exposure exist, protection organizations insist that the benefits of getting diagnosed 
outweigh the associated risks, under most circumstances.10 
Other screening tools including ultrasound and magnetic resonance imaging (MRI) may 
supplement mammography to improve accuracy in detecting breast cancers. Eligible women are 
advised by their referring doctor or radiologist to pursue these adjunct screening modalities. 
Breast MRI targets women who are at high risk for breast cancer due to a strong family history. 
An additional 14.7 cancers per 1000 women are detected when MRI is used in addition to 
mammography and whole breast ultrasound.20 The American Cancer Society recommends it for 
women defined as high-risk (20-25% greater than that of the average woman) or who haven’t 
undergone genetic testing but are first-degree relatives of BRCA carriers.21 MRI requires the 
injection of intravenous contrast to detect differences in blood flow within the breast. A cancer 
typically demonstrates different blood flow compared to the normal tissue that surrounds it. 
Although breast MRI has demonstrated high sensitivity, it is not as specific which may lead to 
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unnecessary biopsies. Some physicians may allow patients to obtain mammography and breast 
MRI in the same visit, while others advise them to separate screenings by 6 months.7 Ultrasound 
also benefits women with dense breast tissue, characterized by excess ducts, glands and fibrous 
tissue and little fat. It is generally harder to visualize tumors in dense breasts via 
mammography.10   
 
 
 
 
 
 
 
 
 
Screening Guidelines  
 
The influence of political actors and stakeholders plays a functional role in constantly 
shifting the recommended standards of practice. Breast cancer screening guidelines have been at 
the center of controversy throughout mammography history. Radiologists, at one point in history, 
were excluded from even joining panels that engaged in the discourse about medical guidelines. 
To facilitate widespread acceptance of guidelines, however, doctors must be mobilized to 
recommend periodic screening to their patients. Government and private insurance companies 
would also need to embrace these new standards in order to cover the costs associated with 
Figure 3. Lateral view of breast positioning during mammography (CancerCareManitoba). 
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screening. Perhaps most importantly, women should be encouraged to partake in the 21st century 
wave of self-advocacy, demanding expanded coverage for medical and screening services.22  
Breast cancer screening recommendations vary from yearly to biennially according to the 
organization. Current practice and proposed guidelines from the U.S. Department of Health and 
Human Services (HHS) and the American College of Radiology (ACR) suggest that women get 
annual mammograms starting at age 40.10 Other major consensus groups and organizations in the 
United States also promote screening at age 40 including the National Cancer Institute, American 
Medical Association, American College of Surgeons, American College of Physicians, American 
College of Obstetrics and Gynecology.7 The American Cancer Society has recently shifted its 
guidelines to recommend annual screening to women at average risk of breast cancer starting age 
45 rather than age 40. They also encourage women to withdraw from this aggressive form of 
screening after the age of 55 and alternatively pursue biennial screening.23  
The National Cancer Institute (NCI) advises women to consider screening at an earlier 
age if they’ve been previously diagnosed with breast cancer or have a family history of breast or 
ovarian cancer. Women at high risk for developing breast cancer may consult their providers 
about obtaining a breast MRI in addition to annual screening mammogram. Most such groups 
recommend breast cancer screening begin at age 40 and women with a first-degree relative 
diagnosed with breast cancer begin annual mammography 10 years prior to the age of diagnosis 
of that relative.10 The United States Preventive Services Task Force (USPSTF) is currently the 
only panel of health care professionals that recommends screening every two years beginning 
age 50 for women at average-risk. It was this very recommendation that sparked a passionate 
debate regarding optimal screening strategies among organizations. 
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Limitations of Mammography  
 
As part of an overt strategy to sow the seeds of screening into standard of care, the 
shortcomings of mammography have rarely been publicly noted. Rather, its potential benefits are 
inflated, causing many women to overestimate its benefits. Deceiving marketing strategies have 
involved plastering images of premenopausal women onto campaign ads, misleading women 
against the well-known fact that they have a higher risk of developing cancer in their later 
years.22 Sensational taglines have broadcasted false information to convince women that they 
have a one in ten lifetime probability of developing breast cancer, historically instilling a sense 
of panic among women. Although these techniques successfully drove up mammography 
screening rates by capitalizing on the fears and ignorance of women, they also left many of them 
lacking adequate patient education about the limitations of mammography.22 The excessive 
acclaim over screening has led some women to wrongly view mammography as a resource for 
preventing the onset of breast cancer.22 In a study by Domenighetti et al. (2003), 68% of women 
were under the assumption that mammography lowered their risk of getting breast cancer.24 
Oblivious to their outstanding risk of cancer-associated mortality despite screening, women may 
experience a wave of outrage or confusion on the off chance they get diagnosed.22 It may also 
disincentivize them from actually engaging in prevention efforts such as getting educated on the 
social and environmental risks that predispose some individuals to breast cancer. 
By framing breast cancer screening as a political issue, we can begin to expose the 
underlying influences behind aggressive screening in the United States. A fixation on early 
detection and mammography has fabricated a “pink ribbon” culture, gaining endorsement from 
groups seeking capital gain.25 A synergy specifically between government and health technology 
manufacturers has encouraged the ubiquity of pink ribbons as well as facilitated the development 
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of national mammography markets. Well-funded and reimbursed screening programs sponsored 
by nations in Western Europe, North America, South Korea, and Japan are correlated with 
mature mammography markets. Mature markets have large investments in infrastructure 
including mammography units and diagnostic centers and show high demand for upgraded 
replacement equipment.26 The U.S. boasts the largest and most advanced mammography market 
with regards to equipment, technology, and available care. It secured substantial revenue 
following the elimination of cost sharing under the Affordable Care Act which boosted rates of 
screening among older women living in areas with the highest quartile of educational 
attainment.27 Strong health infrastructure, participation and coverage among the population has 
triggered a commensurate strengthening of the overall market.  
The rapidly growing mammography global market was valued at 1.43 billion USD in 
2015. It is projected to have a compound annual growth rate of 10.5% between 2018 – 2025 with 
revenue contributions made by rising breast cancer cases and growing awareness about 
preemptive screening.28 Yet, only a handful of manufacturers in mature markets account for over 
80% of global mammography revenues in 2017. Hologic was the largest market share holder, 
with GE Healthcare and Siemens Healthineers following respectively as the second and third-
largest manufacturers. Demand for innovative products that incorporate artificial intelligence, 3D 
tomosynthesis, and patient comfort has been satisfied by products like Hologic’s 3D 
mammography unit, 3Dimensions, and GE Healthcare’s Senographe Pristina.26 The surging 
demands behind advanced screening technology surreptitiously hide many public health 
agency’s diminishing support for aggressive screening. Revenues from the breast cancer industry 
are diffused among the same agencies that have shown unrelenting support for screening starting 
at age 40.  The American College of Radiology owns the trademark for “The Mammography 
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Saves Life campaign.” Siemens and General Electric respectively sponsor the American Cancer 
Society’s Make Strides Against Breast Cancer campaign and the American Breast Cancer 
Foundation.25   
 
 
  
 
 
 
 
 
 
 
 
Observing how technological change has led to health improvements at the disease level 
can help illuminate whether medical spending is worth the increased cost of care.29 Rises in 
healthcare spending have catapulted our nation into a position where we spend the most on 
healthcare relative to comparable countries. In 2000, health expenditures hit about $1.4 trillion 
while doubling to $3.5 trillion in 2017. Figures on spending take into account “healthcare as well 
as health-related activities (such as administration of insurance, health research, and public 
health), including expenditures from both public and private funds.”30 Technological change is 
responsible for a large portion of cost increases over time, as well as many of the benefits that 
have come from modern medicine including “increased longevity, improved quality of life, less 
Figure 4. Global market shares for mammography equipment, 2017 (HIS Markit). 
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time absent from work, etc.”29 Advancements in the sphere of breast cancer diagnostic tools and 
therapies have improved overall cancer diagnosis and treatment rates. Chemotherapy regimens 
have increased in complexity, more frequent surgeries are being performed, outpatient visits are 
offered for drug treatments, while advanced imaging techniques and increased public awareness 
also increase utilization of mammography. However, spending on breast cancer screening and 
treatment has shown that the costs and benefits of these medical advancement are at least of 
equal magnitude. An analysis by Cutler & McClellan (2001) compares population-based survival 
improvements with treatment costs using Medicare claims records in conjunction with data from 
the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. 
Survival after breast cancer increased by four months on average due to increased detection and 
innovations in therapeutic treatment. When valuing a year of life at $100,000 and subtracting 
medical and nonmedical costs of breast cancer, the value of increased survival at least rivalled 
that of costs incurred by technological change.29  
Although screening has shown to reduce breast cancer-specific morality, there is a dearth 
of evidence to show that it reduces overall mortality for people.31 In a systematic review of meta-
analyses of cancer screening trials, 33% showed reductions in disease specific mortality while 
none showed reductions in overall mortality.31 The downstream effects of screening caused by 
false positive results, overdiagnosis of non-harmful cancers, and detection of incidental findings 
may offset these reductions in disease-specific mortality.31 A number of studies have reported 
that some of the cancers detected by mammography would have had no bearing on the woman’s 
health if they hadn’t been found. Only 1 3#  to ½ of DCIS diagnoses would have presumably led to 
invasive breast cancer. But the lack of understanding of how to distinguish between harmful and 
harmless DCIS has led to an increased rate of DCIS diagnoses.22 As a result, these women are 
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forced to undergo risks associated with treatment.22 Conflicting studies indicate that the 
diagnosis of low grade, non-necrotic DCIS lesions occur rarely. Rather, most DCIS detected 
from mammography screening is high grade and necrotic, and appropriately warrants 
intervention.32  The Swiss Medical board has chosen not to recommend mammography given 
that for every 1000 women who undergo screening, breast cancer deaths only decline from 5 to 4 
while non-breast cancer deaths are stagnant at 39 or increase to 40.33 This finding arrives at 
several plausible conclusions; screening either increases non-breast cancer deaths or women who 
are saved from breast cancer die earlier from different causes of death.33  
Mammography diagnoses are fraught with problems of high false positive rates, 
characterized by physicians raising attention to findings that aren’t actually cancerous. The 
percentage of women who are given an abnormal reading and asked to pursue further testing is 
referred to as the screening recall rate.22 Various studies have shown women to have a 30 to 61 
percent chance of getting a false positive result within 10 years of screening if they start at age 
40.1, 3 A biopsy is performed on women with abnormal follow-up mammograms or ultrasounds. 
There is a 7 to 8 percent chance that a woman will also get a breast biopsy within that first 
decade, but most biopsies will demonstrate non-significant results.10 Interestingly, screening 
recall rates for mammography fare much lower in other countries. This may be explained by the 
fact that radiologists abroad are faced with fewer threats of medical malpractice litigation than in 
the U.S.22 
Women with heterogeneously dense or extremely dense breast tissue may also encounter 
greater challenges when it comes to yielding accurate diagnoses. These women have a lot of 
fibrous or glandular tissue (dense tissue) and not as much fatty tissue. While fatty tissue appears 
dark and transparent on a mammogram, dense tissue presents as a solid white area making it 
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harder for a radiologist to see a breast mass or tumor on mammography which also looks white. 
As a result, a correlation between increased breast density and higher false negatives is observed. 
While mammography can already miss up to 15% of cancers, this figure is more exacerbated in 
women with high breast density.22 The sensitivity of mammography ranges from 98% in women 
with fatty breast parenchyma, to 36% in women with dense breasts.3,4 This biological trait can 
also increase a woman’s risk of getting breast cancer by four to six times.34,35 Dense breasts are 
more common among younger women, women with a lower body mass index and women who 
take combination hormone therapy to relieve signs and symptoms of menopause.36 Only some 
states actually require the facility to notify the patient if they have dense breasts. Similarly, there 
is limited coverage for follow-up ultrasounds if radiologists wanted to obtain a more accurate 
visual. For this population of women, full field digital mammography (FFDM) has proven to be 
more sensitive than film-screen (analog) mammography.37 But despite being designated the new 
norm, even FFDM has shown limited accuracy among high-risk younger women.  
 
 
 
 
 
 
 
 
 Figure 5. Categories of breast density. According to the BI-RADS reporting system, 
the levels are (from left to right) almost entirely fatty, scattered areas of fibroglandular 
density, heterogeneously dense and extremely dense (Mayo Foundation for Medical 
Education and Research). 
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Concerns regarding accumulated radiation exposure from digital mammography have 
been broadcasted by popular press and various medical literature. The average mean glandular 
dose (MGD) from digital mammography is 3.7 mGy.38 This is estimated to have a lifetime 
attributable risk of fatal breast cancer of 1.3 per 100,000 women if women are exposed 
beginning age 40. This excess risk decreases if a woman is exposed to yearly screening later in 
life. A risk-benefit ratio demonstrates that for this same group of women, 292 lives would be 
saved as a result of annual screening.39 Given a 36% mortality reduction presumed from 
screening, some researchers argue that the theoretical radiation risk should not discourage 
women under 50 from yearly screening.  Nevertheless, these concerns have driven efforts to 
create new digital mammography technology utilizing lower radiation doses without 
compromising accuracy. For instance, spectral imaging or photon counting eliminates 97% of 
scattered radiation, delivering less MGD to the breast than standard mammography. The FDA 
recently approved a low dose photon counting mammography that has reached popularity in 
other countries. It delivers half the dose of MGD relative to standard FFDM.40   
Moving forward, microscale efforts to promote shared-decision making should be made 
as well as larger funding of intensive scientific trials to fulfill higher standards of evidence 
regarding screening’s benefits. It is within the parameters of the training and medical obligation 
of frontline healthcare workers to advocate on behalf of uninformed patients. Hence, 
transparency and social accountability should be prioritized especially in making sure patients 
are fully informed of how screening affects overall mortality. Raising higher consciousness on 
these processes may catalyze rational, shared decision making between doctors and their 
patients.31 Responsibility should not completely rest on the shoulders of doctors, however – news 
coverage should also contextualize and elucidate this information.25 Additionally, if political 
  
24 
will, public support and financial resources could be mustered to pursue larger randomized 
studies, population-based trends of overall mortality could be explored in relation to screening.  
It’s been suggested that in order to yield conclusive results, 4.1 million participants would need 
to be enlisted in this trial.41 Funds should be reallocated from extensive marketing of 
mammography into supporting screening trials that actively assess its utility.  
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CHAPTER 3: QUALITY OF CARE FROM THE PATIENT’S 
PERSPECTIVE 
 
 Patient feedback is an important source of data for identifying the factors that deter or 
stimulate women to participate in mammographic examinations.42 It may be used towards 
designing effective strategies to capture under-screened populations as well as an indicator for 
measuring the quality of healthcare.43 Previous research has found that interventions to enhance 
the professionalism, empathy, and cultural awareness of technicians are key towards improving 
patient satisfaction and compliance.44 But patient satisfaction is not only correlated with 
characteristics of the microsystem practice but personal factors as well, such as a woman’s 
characteristics, attitudes, and expectations.45 In an effort to fully capture patients’ experiences 
with breast cancer screening, data has been abstracted from surveys, online blogs, or direct 
quotes from eligible women. Giving women a platform to share their mammography experiences 
has in itself shown to be an uplifting and therapeutic activity, particularly if collection of this 
information results in improvements of service delivery.  
Poor repeat adherence rates are stirring up efforts to popularize annual or biennial 
screening among women. Studies estimate that less than 50% of eligible women have obtained 
an annual mammogram for at least 2 years in a row.46-47 Participants who fail to have any 
physical manifestations of breast cancer or haven’t already been diagnosed may ignore 
compliance.44 While access to care and insurance coverage significantly affect a woman’s 
decision to pursue screening, a poor initial experience with mammography may also be a 
predictor of poor follow-up compliance.48,49-50 Literature has documented feelings of 
psychological distress among women undergoing screening. Accordingly, in a survey of 255 
women, 30% of participants claimed that their decision to continue to get screening 
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mammograms was influenced by their first mammogram.51,52 A longitudinal study of 6,898 
women found that having poor experiences during screening mammography is negatively 
correlated with return for futures mammography.53 If these women relay their dissatisfied 
mammography experiences to their family and friends, this may induce a ripple effect in further 
discouraging more women from adhering to screening.54 
Examining the barriers to breast cancer screening among migrant and minority 
communities is necessary to support inclusion of these group members in outreach efforts. In 
2009, the Victorian Cytology Service (VCS) conducted a survey of cancer screening programs 
around Australia and New Zealand. Decreased participation was evidenced in the following 
population groups: indigenous and culturally and linguistically diverse populations, older 
women, men, lesbian women, disability groups and rural or remote communities.43 For the 
purposes of this thesis, a concise systematic review of cancer screening in hard-to-reach 
populations in the United States was conducted using multiple search engines. Based on the brief 
results of this search, this chapter aims to shed light on the experiences and attitudes that 
influence screening behaviors in a diverse group of women including those from the following 
marginalized groups in the United States: disabled women, African American and African-born 
Muslim women in New York City, and American Indian/Alaska (AI/AN) Native women living 
in Kansas and Kansas City.44,55  
 
Fear and Waiting Time 
 
Women’s increased fear or anxiety during a screening visit has been associated with the 
uncertainty of a pending diagnosis. Of the 306 patients who attended a breast clinic, 60% cited 
having anxiety due to fear of cancer and the outcome of the consultation. Most of these women 
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were first-time patients.56 The perceived threat of getting screened may also be rooted in 
misconceptions and a lack of knowledge concerning the screening process. In the Muslim 
community, cancer is not widely discussed as it is a stigmatized topic. But such stigma can 
impact the community on the broader social scale by stifling public discourse that attempts to 
raise awareness about early detection.57 Negative perceptions of breast cancer have subsequently 
driven screening to become somewhat undesirable among African American and African-born 
Muslim women: 
“I know it’s a bad sickness and it kills a lot of people…, it killed my aunt.” 
 
“… Some people think you can contract it because your sister has it or your friend has it.” 
 
“ … (Muslim women) don’t want to do it. They say the radiation makes you get cancer.”  
 
“It’s shame to say that I got cancer.”58  
 
A blog written by Professor Annie S. Anderson for the Scottish Cancer Prevention 
Network articulates a similar narrative embedded in fear, adjusted to her specific identity and 
experiences.59 While in the mammography suite, Anderson speculates whether or not the 
technician would inform her if they noticed any abnormalities on the screen. She is simply told 
that her results would be mailed to her in two weeks. As anticipated, the “clear letter” arrives in 
two weeks, finally putting an end to the troubled thoughts turning over in her mind.59 Anderson 
has a high regard for breast cancer screening, nevertheless, which she claims stems from having 
been previously diagnosed with other serious conditions. Coming to the brave decision to persist 
routine screening despite the looming fear of another diagnosis is understandably very difficult, 
which Anderson describes in her blog: 
“Twice in my life I have been tested for serious conditions and have had positive results, 
so I never undertake screening lightly. I know I will accept screening invitations because 
I know early detection is the key to better outcomes. But, memory and fear are there – 
and have to be confronted.”59 
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Even asymptomatic women without prior history of illness can relate to this heightened sense of 
distress.60 Especially, those who are noticeably treated as high-risk patients: 
“[I] have a history of having to have more views each time I come in. Even though you 
know it is going to happen you are still apprehensive about it. Because you’re wondering, 
what are they going to find today.”61   
 
Surveys show that an overwhelming share of patients would rather hear the results of an 
imaging examination from the radiologist at the time of the procedure than to hear them later on 
from the referring physician.62 This is logistically easier given that if need be, further diagnostic 
studies can be performed while they are still at the facility.63, 64 Women who were originally 
feeling anxious experienced a significant decrease in anxiety levels post-consultation with the 
radiologist. These women presumably received negative results.56 Awaiting the results through 
postal mail, on the other hand, may draw out patient’s nervousness. For one, women may be 
prompted to rationalize the time it takes to receive their results.59 Some women presume a longer 
wait means as that their results are normal versus a shorter wait time suggesting they have a 
positive diagnosis. Even so, this reaction to waiting for postal results does not apply to all 
patients. Some women actually prefer the delay in getting informed of their results as they would 
find it overwhelming to get them the same day as their clinic visit.63  
 
Pain and Discomfort 
 
Pain is a subjective sensation and thereby, difficult to quantify or standardize among a set 
population.65,66 Women generally have dissimilar experiences when it comes to their tolerance 
for discomfort and as a result, they experience mammography differently. In line with this 
statement, the literature shows how patients vary considerably in the sensations they encounter 
during screening. The percentages of patients who reported general incidence of pain across 
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studies include 73% (n = 187),67 66.5% (n = 113)65 and 57% (n = 1514).68 The variance between 
these studies may be explained by discrepancies in data collection methods.66 Pain was 
commonly described using the following language: ‘constraining,’ ‘pinching,’ ‘squeezing,’ 
‘pressing’ and ‘unpleasant.’65   
Breast compression is a specific source of discomfort correlated with overall satisfaction 
with mammography. The machine is responsible for producing uneasy sensations by pinching, 
pulling and stretching the skin.69 In a study of screening patients, 71% found compression to be 
uncomfortable while 43% of respondents (n=20) described the plate as painfully cold.70 
Witnessing their breasts being flattened was equally as troubling for the women.71 The 
compression machine was referred to as “sterile, “cold, “mechanical,” “threatening” and “harsh 
and unrelenting.”71 One individual from a cancer support group expressed how “I thought my 
breast was going to explode.”72 When compression was controlled by the patient rather than the 
technician, women reported significantly less pain and greater overall satisfaction with 
mammography.73  
American Indian/Alaska Native women living in Kansas and Kansas City reported 
feelings of embarrassment in addition to discomfort, given their more conservative views about 
getting undressed.44 They explained that for cultural reasons, AI/AN women do not discuss their 
bodies nor disease. Two women elaborated on how their communities had a heightened emphasis 
on modesty:  
“Well I’ve always found, I bet you have too, in our culture our older people are not ready 
to talk about their private parts. I mean they’re real modest. 
I think prior to my mother being diagnosed with breast cancer, I hadn't worried about it. 
No one had ever talked to us about…you know, she's a nurse, she never talked to us 
about breast self-exams or…but until it happened in our family and now we talk about it 
with like my girls and even our sons.”44 
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Across a collection of studies, women discussed the feeling of being objectified. One woman’s 
experience was akin to being handled like a “lump of meat.”71 Others went on to talk about 
“exposing body parts that one normally doesn’t” and “more touching than is allowed by other 
individuals.”71 The motions of undressing, exposing the body, and touching of breasts were 
particularly unsettling for first time mammogram attendees.74 Nevertheless, a select number of 
women were not bothered by the process and as it happens, preferred that it took place in an 
impersonal context.71  
The expectations women have about mammography have been shown to affect how they 
perceive pain during the test and the satisfaction they feel afterwards.44, 75 The source of these 
expectations about mammography may have been derived from personal anecdotes from family 
and friends.44 In a study where 4% of women reported experiencing extreme pain during the 
examination defended this with “because mammography is a painful examination.”68 The study 
posits that these women may have been persuaded that mammography was inherently an 
uncomfortable technology. This would have biased their expectations before they even got 
examined. Alas, women who experience more pain than they expected have shown to be less 
likely to return for future mammography.53  
Women with disabilities (WWD) may encounter a unique host of difficulties that may 
reduce the likelihood of adherence to preventative screening. Individuals with limited mobility 
were fraught with fatigue at having to stand straight for an extended period of time and spread 
their arms.76 Other hardships experienced by disabled women include poor communication with 
staff or a lack of privacy, particularly among those who experienced accelerated impairments due 
to aging itself.77 Health care providers who are emotionally distant and inappropriately 
stereotype these patients often leave behind a sense of degradation and worthlessness.78 
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Addressing these areas of concern through improved staff attitudes and patient-centered care 
may help carve out a better experience for WWD and promote their continual participation in 
mammography.79 
The technician’s attitude can generally help regulate a patient’s comfort levels during the 
procedure.80 Consolation can be offered to the patient by providing accurate and positive 
expectations about mammography to address any reservations they may have.44 Studies have 
shown an association between receiving information and fewer reports of pain during 
screening.67 The results from a survey show that 80% (n = 197) of women who did not engage in 
conversation with the technician reported pain, as compared to 64% (n=158) of women who did 
converse with them.67 Of course, we would need to be wary of the situation’s causality. In other 
words, did the “technician’s attitude toward the patient influence the woman’s experience itself, 
or did the pain influence the woman’s evaluation of the technician’s attitude?”80  
 
Interpersonal Attributes: Communication and Support  
 
A woman’s experience in the mammography suite is informed by the behavior, attitude, 
professionalism and interpersonal skills of the technician and radiologist.  Patients commonly 
express a desire to be oriented and continuously informed throughout the screening process. 
Given that this process is chiefly headed by the technician, they play a central role in shaping the 
patient’s experience.61,69,72,74 By initiating pleasant conversation, technicians can reduce feelings 
of anxiety and embarrassment among patients.69,72,74  Technicians who practiced clear 
communication and patiently responded to questions were also met with greater patient 
satisfaction. They excelled at keeping the patient informed and effectively managing their 
expectations.61,69,74 Pleased survey respondents, for example, reported that staff “made you feel 
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important.”74 AI/AN Women living in Kansas and Kansas City reported better experiences in 
smaller facilities, having friendly, knowledgeable and respectful technicians. They similarly 
appreciated being guided through the test procedure. Greatest weight was placed on the 
technician’s technical competence and attitude.44,80  
On the other hand, some women left the visit feeling disappointed by the technician’s 
limited effort to provide patient-centered care. Their poor attitude and standoffish demeanor left 
a negative impression. In a study sample of 201 individuals, only 45% felt that the technician 
engaged them conversationally.67  Patients reacted in the following way: “her attitude was bad 
and it made my time miserable,” 69 “didn’t seem interested” and “you were just another 
number,”72 “didn’t talk, she just shoved and pushed,” “if you get treated poorly…you’re for sure 
not going to go back.”69 
A patient’s compliance with screening may also be adversely affected by the lack of 
respectable contact with the radiologist. According to the American College of Radiology, ½ of 
Americans cannot distinguish between the roles of a radiologist and technician.13 In failing to 
appreciate the medical qualifications of the radiologist, patients show more hesitance to follow 
the advice given to them at the time of an examination or procedure.56 Yet, radiologists feel that 
they have the least communication skills training relative to other specialists.81,82 Residents who 
are currently being trained in the field have expressed these same concerns: 
“…attendings often times didn’t want you to come in when they are giving patients bad 
news…a lot of time they think it’s better for the patient to have privacy… that (has a) 
negative effect on our education, just not having the experience.”61 
 
Let’s Talk About Ionizing Radiation 
 
Exposure to ionizing radiation from mammography examinations may increase risk of 
breast cancer among subgroups of women who are often subjected to more frequent screening or 
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possess risk-increasing genetic variations.83,84 Women who are obese or have dense breast tissue 
may be asked to undergo additional evaluations beyond routine screening, rendering them more 
susceptible to radiation-induced breast cancer.85–87 Women with large breasts who are under the 
age of 50 are at twice the risk of developing radiation-induced breast cancer as women with 
small or average breasts. This is mainly attributed to obtaining screening examinations with more 
than four views and above average doses per view.88 Carriers of germline mutations in genes 
involved in the DNA-damage repair pathway (DDRP) have also been shown to have an 
increased risk of developing (contralateral) breast cancer after radiation therapy.89 This has 
important implications for building a safer system of delivering breast cancer screening and 
encouraging patient participation in healthcare decisions.  
Patients at an oncologic center have mixed beliefs and levels of knowledge regarding the 
ionizing radiation generated by medical imaging which generally appears to be commensurate 
with their prior life experiences. A qualitative interview study elicited the views of a diverse 
oncologic population including patients in active treatment, cancer survivors, parents of pediatric 
cancer survivors, and participants in a cancer screening program. The sample (n = 30) was 
primarily female (60%), white (80%), well educated (90% with college degrees), married (50%), 
and employed (52% working full time or part time). Patients who were survivors of testicular 
and lung cancer and patients undergoing screening for lung cancer screening were the most 
knowledgeable about which medical imaging tests involved the use of ionizing radiation. 
Participants who had breast or colorectal cancer and parents of patients with neuroblastoma were 
less capable of making this distinction. It was unclear for many participants on whether magnetic 
resonance (MR) imaging emitted damaging ionizing radiation. Some participants were unclear 
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on how imaging tests measured up to one another and which tests delivered higher ionizing 
radiation doses.90  
Attitudes towards cumulative radiation exposure also vary according to a woman’s health 
status, namely if the woman is undergoing screening, active treatment or if they are a cancer 
survivor. Women undergoing screening mammography prefer the inconvenience of and anxiety 
of continually obtaining false-positive results if it increases the chance of detecting a potential 
cancer earlier. In the same survey population of 1528 women predominantly between the ages of 
40 and 59, 86% of respondents were willing to be recalled for a noninvasive procedure while 
82% demonstrated willingness to be recalled for an invasive procedure.91 Surveys show that this 
opinion is more concentrated among individuals without current disease. Patients who have 
previously reaped the benefits of having their cancers detected by imaging tools were also less 
inclined to inquire about long-term risks from ionizing radiation. The perception of medical 
imaging is slightly different among those with active or residual disease. Some patients at an 
oncologic center expressed frustration at their inability to differentiate between imaging tests and 
were concerned about the harm inflicted by overutilization.90 Yet for most of them, immediate 
survival was a more pressing concern, weakening any lingering interest in the long-term 
potential risks of ionizing radiation.90  
Discussions with patients on the benefits and risks of long-term exposure to ionizing 
radiation are not frequently prioritized among clinicians. Most oncological patients report never 
having discussed these matters with their provider while only a select few directly questioned 
their doctor, nurse, or technician about it. Among this small group of patients, a majority were 
disappointed by the lack of thoroughness and clarity in their responses. Time constraints may be 
shaping this trivializing behavior, as professionals are forced to hop from one patient to the next. 
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A testimonial from a radiology resident highlights the frustration they feel towards building 
rapport with patients under limited time: 
“We…[have] such a snapshot interaction with the patient…on our part sometimes there is 
this hesitation because we are not familiar with the patient, and so we don’t necessarily 
have the rapport with patient.”61  
 
Patients who were the most intrinsically motivated to understand the risks of repeated exposure 
to ionizing radiation were survivors of cancer. They were willing to strike up a benefit-risk 
conversation as a way to build trust with their provider. Some participants, however, imbued 
sufficient trust in their provider and did not find it necessary to initiate this type of conversation. 
For a few, prompting this discussion seemed outrageous and frightening. Most individuals 
agreed, however, that routine care should at least make benefit-risk information accessible for 
interested parties.90 Breast center staff should also put more effort into averting radiation-induced 
breast cancer by discussing with patients the possibility of delaying screening to age 50 or 
pursuing biennial screening as an alternative to annual screening. These changes would have a 
combined effect of lowering patient’s risk almost five-fold.88   
 
Breast Density Notification 
 
High breast density (BD) is common, 40-50% of women ages 40-74 have dense breasts 
in the United States.92,93 It is a risk factor for developing breast cancer and is associated with a 
higher likelihood of an interval breast cancer in mammography screening.94 For women with 
dense breasts, adjunct screening such as breast ultrasound and digital breast tomosynthesis may 
help detect additional cancers not detected on mammography.95–97 However, because follow-up 
screening is considered diagnostic, most states do not require full insurance coverage of 
supplemental imaging for women with dense breasts. The first law in the country was enacted in 
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New York which requires insurance companies to cover all screening and diagnostic imaging 
exams for the detection of breast cancer.98  
Notifying women undergoing mammography of the risks associated with their breast 
density is mandated in 32 states.99 A growing patient advocacy movement pushing for informed 
decision-making gave vitality to this new legislation. Just recently, the Food and Drug 
Administration broadened the scope of this law by proposing a new rule that mandates all breast 
centers nationwide to use specific language to notify women if they have dense breasts and to 
explain breast density. According to Dr. Jenn Shuren, director of the agency’s Center for Devices 
and Radiologic Health, this would be the minimum requirement, leaving it to the state’s 
discretion to include more information in the notification.100 Nonetheless, given the associated 
adverse outcomes of false-positives, significant costs, and the possibility of overdiagnosis from 
increased supplemental screening, it is debatable whether notifying women on BD confers any 
net health benefits.101 This may suggest a need for establishing formal methods to evaluate the 
effects of enacting BD notification laws.  
Clinically integrating the concept of patient autonomy remains a key area of 
improvement for medical practices. Primary care physicians report lacking the necessary training 
to address BD-related issues and to make appropriate recommendations to patients.102–104 
Radiologists also appear uncertain on how to manage new legislation and imaging 
recommendations.99,105–109 Presumably due to poor information flow between providers and their 
patients, knowledge of breast density among women receiving routine mammography remains 
inconsistent. A survey assessing breast density awareness and knowledge was administered to 
all women following implementation of mandatory breast density notification in Massachusetts. 
Out of 338 women, 54.7% self-reported having dense breasts but only 61.1% associated 
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their breast density with increased breast cancer risk. Women with dense breasts (63.8%) had a 
stronger intention to follow-up with their provider as well as seek supplemental screening 
(45.1%) in comparison to women with non-dense breasts (50.8% and 15.4%, respectively).110 
Many patients, however, faced financial barriers that prevented them from complying with 
recommendations for follow-up imaging.111 Larger healthcare organizations which carry more 
political and economic clout, should be called on to offer support to individual clinics, 
physicians, and other healthcare providers as they navigate BD notification legislation. Providers 
should receive formal training on discussing relevant information about breast density and its 
associated risks with their patients. In recommending next steps, they should also be mindful of 
financial costs incurred by supplemental screening.112,110 
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CHAPTER 4: CHARACTERISTICS OF HIGH-PERFORMING 
MICROSYSTEMS 
 
 
A healthcare organization referred to as the macrosystem is responsible for coordinating 
and overseeing the smaller microsystem units it is comprised of. The clinical microsystem refers 
to a functional, replicable unit of the healthcare organization consisting of clinicians and staff. 
This core team of health professionals works interdependently with a shared clinical purpose of 
providing care to a population of patients.113–115 To perform a set of tasks associated with 
delivering healthcare, certain elements of the microsystem are necessary. These core elements 
include a specific type of care process, clinicians and support staff to engage in these processes, a 
specific patient population, an information environment, and technology to support providers and 
patients.113A few examples of clinical microsystems include a family practice, cardiovascular 
surgical care team, a community-based outpatient care center, an emergency department or a 
neonatal intensive care unit.116 Microsystems are flexible, adapting according to the needs of the 
people they engage with directly. They can also respond to external demands from larger 
macrosystems.117 But in order for a microsystem to evolve over time, actors working within 
these units should be encouraged to innovate and continually build their expertise.  
The complexities and obscurities of healthcare institutions not only lead to patient 
discomfort and harm, they also incur excess costs. An operational microsystem can help stop, 
prevent or diminish errors that pose a risk to patient safety by increasing the unit’s awareness of 
its functioning as a microsystem.6,117 By being mindful of one’s individual purpose within a 
system, individuals can critically reflect on their work and recognize lapses in service quality. 
According to Weick and Sutcliffe, becoming more mindful means microsystems are 
“preoccupied with failure, reluctant to simplify interpretations, sensitive to operations, 
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committed to resilience and deferent to expertise.”118 Briefly, this means becoming alert to front 
line errors and consistently acquiring new information to nuance their understanding of complex 
problems. This also means finding innovative solutions to recover from errors, many of which 
should come from individuals with the most expertise, irrespective of their authority level.118  
Since the larger macrosystem is only as effective as the units of which it is comprised, 
organizational level efforts to mitigate error should be carefully tailored to the ecology of the 
individual microsystem. Organizations that continually develop and organize around the 
frontline relationships with the clientele they serve regularly deliver high quality services and 
possess an outstanding reputation among their customers.117 Hence, frontline innovations can be 
used to develop high-performing health care systems. This would especially benefit patients who 
present multiple chronic health problems complicated by various social factors.119 High-risk 
patients receiving personalized care obtain more coordinated care and exhibit greater 
satisfaction.120  
Microsystem assessment tools have been developed to help team members identify areas 
for improvement and increase the potential for delivering higher quality and safer care. Their 
robust frameworks help clinical teams develop a sense of identity as a system and explore ways 
to incorporate change in how they function. This concept has been derived from statistician and 
consultant W. Edwards Deming and business school professor James Brian Quinn. Drs. Paul 
Batalden and Eugene Nelson, professors at Dartmouth College were responsible for 
extrapolating this work to the healthcare sector.5 Since then, methodological approaches to 
examine microsystem performance have been produced giving rise to instruments like the 
Clinical Microsystem Assessment Tool (CMAT). The CMAT has been commonly used to 
examine microsystem performance according to the 10 key characteristics: leadership, 
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organizational support, staff focus, education and training, interdependence, patient focus, 
community and market focus, performance results, process improvement, information and 
information technology.121 Similarly, The Malcolm Baldrige National Quality Award (MBNQA) 
establishes guidelines for organizational quality assessment and improvement. Since its creation 
in 1988, it has been used by various sectors of the economy including business, healthcare and 
educational organizations.122   
In 2002, an assessment tool by Mohr and Batalden emerged from a qualitative analysis of 
interviews from 43 microsystems in North America. Given its success in thoughtfully 
incorporating the voices and feedback of individuals who are directly represented in 
microsystems in the U.S., this diagnostic will be used to thoroughly assess breast centers in this 
thesis. The common dimensions identified across these microsystems should not be thought of as 
mutually exclusive, but rather, overlapping and complementary. According to this body of 
research, the eight qualities associated with high performing microsystems include integration of 
information, alignment of role and training, measurement, interdependence of the care team, 
supportiveness of the larger system, connection to the community, constancy of purpose, and 
investment in improvement.6 
 
Integration of Information  
 
“Microsystems vary on how well information is integrated into its daily work and the role 
that technology plays in facilitating the integration.”6 
 
Information transfer between the technician and interpreting radiologist has been integral 
in preserving patient safety especially in the midst of a healthcare imaging evolution. Prior to 
filmless imaging, staff were positioned in a central working area which enabled frequent in-
person contact. These interactions promoted peer-to-peer education and quality assurance of 
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imaging studies through improved communication and joint case review.123 Radiologists and 
technicians positioned in this group dynamic also interacted with other medical specialists who 
had to travel to the imaging center to review their patient’s films. The digitization of medical 
imaging through picture archival and communication system (PACS) historically induced a shift 
in the design of the workplace floorplan. Radiologists and technicians, no longer dependent on 
their proximity to diffuse information, dispersed as independent actors to increase their 
operational efficiency.123 The technological transition to teleradiology in the late 1990s further 
ostracized radiologists from their clinical team.124 A marketplace for outsourcing services in a 
distributed model was created, upon which a decline in consultations with immediate coworkers 
as well as referring physicians ensued.124, 125 Some innovations, however, have impacted work 
relations in a net positive manner. The Electronic Medical Record (EMR) systems provides an 
avenue of communication through the digital sharing of patient charts. However, its utility 
hinges on the radiologist’s voluntary will to read the notes and information collected by the 
technician during the patient’s visit.  
Although new innovations have become adaptable to the imaging landscape, they have 
noticeably scarified the technical quality of medical imaging data. The former centralized layout 
of the radiology department enabled a more quality assurance (QA)-focused environment as it 
offered a space to gather and collectively review films. The radiologist reading room was 
positioned nearby the technician’s viewing area, promoting frequent consultations regarding 
image quality. Although the interactions in this space precipitated a friendly and social 
atmosphere, constructive criticism still had a stronghold over peer-to-peer relations. Staff 
mutually gained from one another’s diverse skill sets and hosts of knowledge.126 Newly 
practicing professionals would likely profit most from this training opportunity given that they 
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are the most susceptible to diagnostic inaccuracies. Caseloads were also relatively lower, and 
reimbursements were generally higher which initially afforded more time and attention to quality 
assurance practices. Over time, technology vendors centered their research and development 
efforts on market economics. Productivity became correlated with cost-effectiveness and revenue 
rather than quality which was not as easy to quantify. The untimely decline in reimbursements 
further pushed imaging providers to concentrate efforts on increasing productivity.  
External sources of interpretive error have been bred out of pressures to comply with high 
imaging volumes in order to obtain reimbursement by third-party payers.13 Time-consuming 
work compounded with already lengthening work-days, has been shown to increase rates of 
misdiagnosis and compromise the efficacy of mammography. A study documented radiologists’ 
weakening visual accommodation and declining performance by the end of the work-day.127 
Factors such as inattention, fatigue or lack of experience have been correlated to high false 
negatives.2 False negative outcomes can jeopardize patient safety by delaying delivery of 
treatment as prognosis worsens.2 Distractions and multi-tasking have also been noted as other 
sources of interpretive error.128,129 Beyond interpreting images, the job of the radiologist may 
require them to consult with referring physicians, answer phone calls and return pages.130 A 
study by Balint et al. showed that an increase in average phone calls an hour before a preliminary 
report was due increased the odds that a resident would make an error by 12%.130 In an effort to 
control escalating demand for medical imaging, it is imperative that we make a stronger 
commitment to QA and to incentivize data-driven quality improvements in imaging quality.126   
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Alignment of Role and Training  
 
“Alignment of role and training suggests that there is a deliberate effort within the 
multidisciplinary team to match the team member's education, training, and licensure 
with their role.”6 
 
Job dissatisfaction and poor employee performance can have far-reaching effects on the 
quality of patient care and safety.131 Studies over the years have explored important variables 
related to mammographic radiologist and technician job dissatisfaction. Radiologists are 
reportedly demoralized by the risk of malpractice litigation which may drive them to doubt their 
medical decision-making capabilities. Other unsatisfied radiologists find mammography to be 
tedious.132 Technicians’ discontentment, on the other end, often stems from a negative 
relationship with the radiologist they work with or other fellow mammographic technicians.131,133 
Technicians in the UK reported experiencing occupational stress due to difficulty 
communicating with the patient while the biggest indicator of job dissatisfaction for them was 
role ambiguity.133  
Physicians who incorporate a degree of familiarity in their relationship and 
communication with technicians can help improve the overall performance of the microsystem. 
Technicians empowered to offer their opinions or take initiative on a protocol makes for a 
smoother workflow, with fewer interruptions to the radiologist and greater assured patient safety. 
Radiologists and technicians can strengthen their relationship by building trust, communicating 
expectations as well as honoring a tech’s workstyle. Sharing research projects, passing along 
positive feedback, and technology tricks to facilitate workflow are additional ways to create a 
stronger team.134 
Forming an interdisciplinary team will cultivate a culture of mutual support and respect. 
Studies show that mutual respect underscores the significance of each team member in the group, 
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making them feel valued and appreciated. This may help undercut the internal and external 
environmental factors possibly driving insecurity in their professional identity. These individuals 
are subsequently more likely to be committed, creative and contributory towards the final goal. 
Not only do team members feel more comfortable fully participating in the group dynamic by 
raising issues and questioning ideas, they receive constructive feedback in return. Effective 
interdisciplinary teams also display strong mentorship through formal or informal mentoring. 
Infusing these practices and values into the social fabric of the microsystem is expected to 
stimulate personal growth and overall clinical performance.135  
 
Measurement 
 
“Effective microsystems measure what they do and recognize that the measures at the 
macrosystem level are not always helpful at the microsystem level. Part of the work of 
the microsystem becomes the development of a set of measures that are appropriate for 
the goals of the microsystem.”6 
 
Standards and performance metrics are used to drive up quality.136 The Mammography 
Quality Standards Act requires mammography facilities to regularly review medical outcomes 
associated with diagnostic mammography.137 Diagnostic mammography is performed as an 
additional assessment following abnormal screening findings or following the discovery of a 
palpable lump. The American College of Radiology calls for more comprehensive auditing that 
entails separate screening and diagnostic mammography data.138 According to the U.S. Food and 
Drug Administration, as of January 2019, 99% of currently certified mammography facilities in 
the United States use digital mammography.139 A transition from film to digital mammography 
has swept across imaging centers over the last decade. This has been followed by increased 
abnormal interpretation and cancer detection rates and decreasing positive predictive value 
(PPV2) of a biopsy recommendation.140  
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Performance benchmarks in the United States for modern diagnostic digital 
mammography are updated annually from the Breast Cancer Surveillance Consortium (BCSC) 
and describe the range of performance in clinical practice.140 Six geographically diverse BCSC 
registries were consulted for data on 401,548 examinations conducted from 2007 to 2013 in 
265,360 women linked with cancer diagnoses.140 The demographics of the population were also 
collected which included age, race and/or ethnicity, family history of breast cancer, and breast 
density. Metrics used to gauge performance include the cancer detection rate, abnormal 
interpretation rate, positive predictive value (PPV) of a biopsy recommendation (PPV2), PPV of 
biopsies performed (PPV3), false-negative rate, sensitivity, and specificity.138 
The Breast Cancer Surveillance Consortium reported that more than 75% of radiologists 
met the acceptable ranges for cancer detection rate, abnormal interpretation rate, and sensitivity. 
Fewer radiologists performed up to par with the accepted standards for PPV2 and PPV3. Only 
53.1% of radiologists operated within the acceptable range for PPV3 in their evaluation of a 
palpable lump while fewer than 70% were within the acceptable range for specificity. Trends in 
the data show that radiologists are exceeding the recommended limit for false-positive biopsies 
albeit a majority are effectively detecting cancers.140  
Relative to the United States, European countries have been successful in achieving 
higher specificity levels in diagnostic and screening mammography, while sensitivity 
performance measures remain similar.141–144 NHS Breast Screening Programme standards are 
delivered by 80 services across England and are used to screen over 2 million women each 
year.136 There are now 17 core standards that cover the screening pathway experienced by a 
patient.145 Reports on performance are given at both the service level and individual 
mammogram reader level. To determine overall performance of the screening, sensitivity and 
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specificity of invasive cancers are most commonly used. Yet, it is difficult to yield an instant 
assessment of how many women received true positive or negative results immediately after they 
get their mammogram. Women with interval cancers or next round screen-detected cancers may 
have their status as true negative or positive validated later on in time. Hence a more accurate 
estimate of performance, according to the NHS, has been cancer detection rate and recall rate. 
A microsystem’s commitment to develop clinical performance measures that drive 
improvement may manifest in unique and innovative ways. In an interview of 43 microsystem 
leaders, nearly half measured performance levels using clinical, functional or financial 
indicators. A few used national guidelines and benchmarks to compare their performance. 
However, one representative spoke out against this technique, claiming it confers tunnel vision:  
“We measure success against ourselves. We try very hard not to measure against 
benchmarks. Benchmarks can limit you. Sometimes the benchmarking in and of itself 
becomes the goal.”146 
 
Other strategies employed by microsystems to monitor clinical performance include tracking the 
types of protocols used by physicians and their adherence to those protocols. Forty-four percent 
of microsystems in this study measured patient satisfaction levels while fewer also assessed 
provider satisfaction. Not every leader interviewed was cognizant of how their performance 
measured across different indicators, and reasonably so if they lacked formal methods for data 
collection. Described by some as an arduous task, clinical monitoring requires extensive 
resources. While some microsystems are discernably committed, others may not value it enough 
to put in the necessary time and effort.146   
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Interdependence of the Care Team 
 
“Microsystems with a high degree of interdependence are mindful of the importance of 
the multidisciplinary team approach to care, whereas those with a lower degree of 
interdependence are characterized by providers and staff working as individuals with no 
clear way of sharing information or communicating.”6 
 
Establishing a collaborative model of care as an extension of integrated care will increase 
the efficiency, availability and effectiveness of breast clinic services. The division of labor has 
historically spurred organizations to grow and specialize on separate terms. This has left behind a 
fragmented system, where complex organizations are working in silos, inadvertently impacting 
quality, cost and outcomes. Breast centers have evolved significantly since when they were first 
launched.14 Previously, these centers were loosely defined on whether they solely offered 
mammography or offered a wider array of services.14 Now, many are pursuing innovative 
models that coordinate care among healthcare providers to provide a continuum of services to 
their patient populations.147 The addition of coordinated multidisciplinary teams has considerably 
improved the quality of delivered services. Teams consist of professionals who specialize in 
responding to different health and human services, including doctors, nurses, technicians, social 
workers, etc. They often assemble in meetings termed “pretreatment breast conferences, 
comprehensive breast conference, tumor board, or simply breast conference”14 This collaboration 
demonstrates a holistic commitment to treating an individual and also facilitates a warm hand-off 
to other healthcare providers in the case that a patient must advance beyond the screening 
process.  
The National Accreditation Program for Breast Centers (NAPBC) is administered by the 
American College of Surgeons and accredits centers that provide a range of cancer care 
resources. These centers demonstrate quality in categories as leadership, clinical management, 
research, community out-reach, professional education and quality improvement. NAPBC-
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accredited centers embrace the entire spectrum of cancer care, providing women with access to a 
range of board-certified specialists, including breast surgeons, breast radiologists, medical 
oncologists, radiation oncologists, breast pathologists, plastic/reconstructive surgeons, genetic 
counselors and psychosocial support professionals.148 Accredited centers also offer breast nurse 
navigators, patient education and support, palliative care programs, survivorship programs and 
high-risk clinics. To be accredited, a breast center must provide all of these services in one 
setting or provide most of the services on-site and have referral processes in place for other 
services. 
It is frequently stated that “no one model fits all” and accordingly, it is up to 
microsystems to use a bottom-up, patient centered approach to implement an integrated care 
model that enhances their capacity to provide safe and cost-effective care.149 By capitalizing on 
the abilities of each team member, clinics can more readily provide comprehensive services 
including preventative education, screening and diagnosis. Of course, the process of constructing 
this collaborative model will be dynamic. Each member of the team will have to figure out how 
they can best contribute or “develop areas of expertise” in improving the patient experience. 
Technicians are an underutilized resource in delivering comprehensive care, specifically during 
screening mammography. Because they are at the frontlines of patient care, their services are a 
determining factor in the patient’s satisfaction and subsequent compliance with screening. 
Hence, while establishing a collaborative model, it is important we take into consideration the 
great potential of technicians in optimizing patient healthcare delivery. Ultimately, the goal 
should be to promote quality of care while preserving patient autonomy. This is characterized by 
ongoing communication between team members, and between healthcare providers and their 
patients. This not only improves patient satisfaction, particularly in the area of decreasing 
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women’s anxiety throughout their visit, but also boosting their sense of self-efficacy.150 Patients 
may be more activated to advocate for themselves as they navigate the healthcare system.151 
 
Supportiveness of the Larger System 
 
“The larger organization may be either helpful or “toxic” to the efforts of the 
microsystem.”6 
 
A microsystem’s ability to provide safer care to its patients may be conditional upon the 
leadership of the larger healthcare organization it reports to. The Health Care Advisory Board 
claims that successful organizations follow a “tight, loose, tight” management strategy of their 
microsystems.152,153 This would entail having microsystems within an organization position their 
mission, vision and strategies in “tight” accordance with those of the organization.6 They are 
simultaneously given the freedom to evolve in order to achieve their mission of providing safer 
care, while still under the management of “senior leaders” in the microsystem.6 Although 
microsystems are given the freedom to pursue quality improvement efforts, they should also be 
entitled to organizational support to integrate these efforts into their daily work.146 
Breast center microsystems and providers are encouraged to comply with screening 
recommendations from national guideline committees, cancer societies or leagues, and specialty 
societies. The incongruence between screening recommendations from these organizations may, 
however, be jarring for providers within the microsystem. There is disagreement over which age 
mammography should be initiated and discontinued, as well as the optimal screening interval. 
Other than within the USA, there is no significant difference in the intensity of screening 
guidelines globally. Mammography recommendations from the American Cancer Society, 
American College of Obstetrics and Gynecology, and American College of Radiology 
recommend annual screening with longer screening intervals for patients at average risk. The 
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American College of Radiology is the sole organization that recommends aggressive 
mammography annually beginning age 40 for this same population of women, while failing to 
specify the age upon which women should stop getting mammography.154  
Despite the USPSTF and ACS recently promoting less routine use of mammography, 
there has been little documented change in screening practices among patients. Among primary 
care physicians in 2016, 80% of 871 surveyed participants said they would continue 
recommending screening to women between the ages of 40 and 44 contrary to the recommended 
guidelines.155 Patients’ behaviors also showed minimal adjustment to revised guidelines.156  
Some researchers link this obstinate behavior to the fact that patients and physicians 
overestimate the benefits of mammography in reducing overall mortality. Fear of malpractice 
litigation due to delayed breast cancer diagnosis in symptomatic patients may also be a 
contributing factor, as may be the U.S. fee-for-service payment system. Difficulty engaging 
patients in shared decision-making may also hamper physicians’ efforts to offer personalized 
screening. Women’s adherence patterns to mammography are associated with other external 
factors according to a survey by The Centers for Disease Control’s Behavioral Risk Factor 
Surveillance System (BRFSS). Adjusting for insurance status and frequency of medical 
checkups, increasing frequencies of screening are correlated to rising age. Women without 
access to healthcare were not afforded the same privilege of adhering to any recommended 
mammography screening guidelines.157 Patients who had not received a medical check-up within 
the last 5 years were shown to be less likely to adhere to mammography screening.157 Poor 
adherence is commonly associated with advanced-stage breast cancer in low-income 
populations.158  
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Physician’s recommendations for screening appear to be correlated with differential 
alliance and affinity to certain agencies. A survey filled out by general practitioners, internal 
medicine doctors and gynecologists gauges their confidence in various breast cancer screening 
mammography guidelines. Of all survey respondents, 26% said they trusted the ACOG breast 
cancer screening guidelines the most while 23.8% reported trust ACS guidelines; 22.9% trusts 
USPSTF guidelines. Accordingly, physicians who allied with ACS and ACOG guidelines were 
significantly more likely to recommend screening younger women as compared to physicians 
who trusted USPSTF guidelines.155 This survey suggests that physician adhere differently to 
guidelines, while other studies have shown that these adherence patterns are influenced by their 
own society’s recommendations. For example, referral rates are significantly lower among 
family and internal medicine physicians whose USPSTF society recommends biennial screening 
starting at age 50 years. Obstetricians and gynecologists, on the other hand, demonstrated stable 
mammography referral rates over time. Their society continues to recommend annual screening 
starting at age 40 years. Patient who regularly see obstetricians and gynecologists are hence more 
likely to be encouraged to receive screening mammography as compared to their counterparts.159  
 
Connection to the Community 
 
“Connection to community represents a symbiotic relationship between the microsystem 
and the community that extends well beyond the clinical care of a defined set of 
patients.”6 
 
Under the age of 45 years, African-American women demonstrate higher incidences of 
breast cancer.160 Cancer data show that 30-40% of African-American breast cancer patients are 
younger than 50, compared with 20% of Caucasian-American breast cancer patients.161  
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African-American women are also more frequently diagnosed with late-stage breast cancer.162 
Triple negative/basal-like tumors which are more prevalent among African-American women 
have poorer prognosis compared to other subtypes of breast cancer within the first 5 years after 
diagnosis.163–169 This molecular subtype of breast cancer is also more common among Hispanic 
women relative to non-Hispanic white women.170–172 Lifestyle factors can contribute to the 
higher rate of triple negative breast cancer among African-American women, all of which may 
explain why African-American women face higher breast cancer mortality rates.163,173–176  
  Evidence of complex socioeconomic, cultural and biological factors may help elucidate 
the disparities in breast cancer outcomes between African-American and Caucasian-American 
women.177–180 It is widely understood that the poor social and economic conditions permeating 
African-American communities have given rise to health inequities. African-Americans are 
twice as likely to lack medical insurance or rely on public insurance such as Medicaid compared 
with Caucasian-Americans. Such barriers to healthcare access have been shown to discourage 
adherence to routine screening.158 The underutilization of genetic counseling services also delays 
breast cancer diagnosis and treatment.181–183 Additionally, the younger age distribution of 
African-American breast cancer patients has been linked with the higher prevalence of early 
childbearing that is observed among African-American women. A short-term increase in breast 
cancer risk occurs in the postpartum period and is correlated with premenopausal breast cancer 
risk.184 A similar concept explored by Palmer et al. (2003) demonstrates how multiparity 
increased breast cancer risk prior to the age of 45 years but was protective against breast cancer 
risk after age 45 for African-American women.185 Findings have suggested that a lack of 
physical activity and inadequate intake of vitamins and minerals may also contribute to a pre- 
and postmenopausal breast cancer risk among this demographic of women.186 
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Investing in community outreach to improve mammography utilization rates has been 
integral in reducing ethnicity-related disparities in breast cancer survival.174 It’s important to 
acknowledge national data which shows that differences in mammography screening rates 
between African-American women and Caucasian-American women has been narrowing. Since 
breast cancer outcome disparities persist, a multi-pronged public health approach may be most 
effective at reducing associated mortality rates.174 NAPBC-accredited centers engage in breast 
disease education, prevention and/or early detection programs in collaboration with other 
facilities or local agencies. They aim to help women reduce their risk by informing them of 
healthy lifestyle behaviors and chemoprevention, providing genetic counseling to high-risk 
populations, and offering screening services and clinical examinations. Patients who turn out to 
have positive findings are offered follow-up services. NAPBC standards also require that centers 
provide patients with educational information covering evaluation and management of breast 
diseases.148 However, resources should not be exclusively tailored to diagnosed populations but 
relevant to the needs of women from all populations. Specific outreach to the African-American 
community can be optimized through survivor advocates, social networks, and church-based 
support groups.187–191 The Sisters Network, Inc. is a notable national African-American survivor 
advocate organization whose mission is to spread awareness on breast health and increase 
accessibility to clinical trials.192 Increased participation in outreach programs may also boost the 
likelihood of research endeavors.174  
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Constancy of Purpose/Investment in Improvement  
 
“An important characteristic of a microsystem is that the aim… is consistent with the aim 
of the larger system and guides the work of the microsystem. An investment in 
improvement comes in the form of resources such as time, money, and training, but 
above all it involves creating a philosophy of improvement within the microsystem.”6 
 
To establish new norms in the workplace, clinical teams must be committed to building 
change into the fabric of their microsystem. Developing an expanded monitoring program may 
help improve awareness of the team’s performance as well as each individual’s role within the 
team. But perhaps even more importantly, improving mindfulness in the workplace can 
encourage individuals to thoughtfully process their responses to demanding and stressful 
situations. This reflective process not only facilitates continuous learning, but also helps 
professionals recognize the external factors driving error like the fact that “the world they face is 
complex, unstable, unknowable, and unpredictable.”6 They face growing demand for their 
services alongside declining reimbursements and new technologies that enable increasing 
productivity. These mounting challenges call for the need to prepare team members to become 
compassionate towards themselves and resilient in their commitment to provide quality care. 
Practicing mindfulness can be the first step in making the link between safety and the 
microsystem.6 
Dynamic leadership that promotes the use of reflective practices and team-building 
exercises can help spearhead the crusade for creating a culture of mindfulness. As a form of 
“tacit knowledge,” mindfulness is a state of raised consciousness that is best learned through 
“observation and practice.”193 Leaders can cultivate mindfulness among staff members by setting 
an example of how they personally react to chaos and the unknown. Team members may also be 
engaged through versatile mindfulness interventions that have been created to specifically fit into 
the routine of individuals working in a healthcare setting. A systematic literature review of brief 
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mindfulness practices for healthcare providers identified virtual interventions including on-line 
modules, audio CDs or smartphone apps that give people the flexibility to practice at home.194 
Practices vary and can involve a combination of the following activities: “general mindfulness 
practices such as increasing awareness, presence, or acceptance through breathing meditations, 
mindfulness-based stress reduction-inspired content, Buddhist Anapanasati breathing meditation 
or Vipassana meditation.”194 Group sessions can also facilitate team-building within the unit, 
allowing for the emergence of collective mindfulness. This type of training has been associated 
with improvements in personal well-being, connection to self and patient, error recognition and 
medical decision-making.193 
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CHAPTER 5: PERSONALIZED RISK-BASED APPROACH 
 
Shifting the current paradigm from mammography to a more flexible breast cancer 
screening regimen may be the most effective option for optimizing health outcomes. We should 
continue to aspire towards producing new and improved breast cancer screening tools. In tandem 
with this new technology, a personalized risk-based approach is necessary to tailor health 
decisions and interventions to an individual’s unique risk factors. This approach attempts to 
combine various practices and imaging techniques to maximize specificity and sensitivity while 
minimizing cost and radiation exposure.7 This will also predictably ease patient anxiety and 
concern about radiation exposure which has been shown to decrease compliance with screening 
recommendations.195 An example of a standard stratified screening program that uses an array of 
biomarkers would be as follows: “offer of stratified screening, risk profiling, delivery of 
screening, communication of results, and further management.”196 
In order to fully implement a personalized risk-based breast cancer screening and 
prevention program, a host of stakeholders must be mobilized. The medical community has 
begun to rally around the concept of tailoring screening regimens to a woman’s overall risk 
profile. Medical education for health professions will be necessary to reinforce this screening 
program as this new approach requires assessments to be made over longer periods of time and 
hence, foster  “greater interaction between service providers and the target population.”196 This 
way, screening frequency and modality may be adjusted to “potentially optimize the harm-
benefit ratio of mammographic screening” for different subgroups of women.196 In defiance of 
most recommended screening guidelines in the healthcare industry, the U.S. Preventative Service 
Task Force (USPSTF) and American Cancer Society (ACS) have boldly displayed their support 
for risk-based breast cancer screening.197 As an independent agency, the USPSTF is not 
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implicated in any conflicts of interest.25 However, currently there is little evidence of prevention 
advice being integrated in population-based breast cancer screening programs.196 Prevention 
refers to both primary prevention and early detection (secondary detection).198 Figure 6 presents 
an implementation scheme of a sample risk-based screening and prevention program from the 
National Institute for Health and Care Excellence (NICE).199   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Implementation of a risk-based screening and prevention program  
(National Institute for Health and Care Excellence (NICE)).  
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Risk Stratification & Shared Decision-Making 
 
Stratified screening will be offered on the basis of age as well as risk profiling, which has 
been shown to increase accuracy in discovering higher-risk individuals. This is expected given 
that our ability to estimate an individual’s risk of developing cancer can be exponentially aided 
by exploring the genetic basis of disease susceptibility.198 Programs offering stratified screening 
will have to delineate what information is given to prospective patients and ensure that it is made 
comprehensible to patients of varying educational and ethnic backgrounds. Most importantly, the 
program must have a protocol for enlisting the consent of participating individuals. 
Accommodations should be made for individuals who refuse risk stratification but still have a 
desire to get screened.198  
The variations of risk assessment stem from the following core evaluations: genetic 
testing, assessment of non-genetic risk factors and the integration of genetic and non-genetic 
information into a risk score/risk category. Genetic DNA will need to be accessed in order to 
perform sequence analysis and ultimately carry out specific risk assessments. Preceding any 
invasive course of action will be a thorough discussion of which high-risk variants to include in 
the risk assessment based on the advantages they would confer to the patient. Deleterious 
mutations in BRCA1 or BRCA2 are often related to a risk of breast cancer. A strong family 
history of cancer may prove to be reasonable suspicion for testing for such high-risk alleles. 
Additional variants may be tested over time as more evidence accumulates. Surely if whole 
genome sequencing becomes more routine as a prevention tool in the distant future, younger 
individuals may be enlisted in the program. Genetic counseling may be sought following testing 
to translate test results, provide support options to the patient and/or appease potential frustration 
and concerns. Additionally, caution should be taken to securely store samples and data as well as 
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protect them from being abused for reasons not agreed upon by the individual. 198 Non-genetic 
information to assess risk may also be collected via a questionnaire that elicits reproductive 
history, past medical history, family history, environmental exposures, and lifestyle information. 
Because this information is less stable throughout life, it may have to be obtained from the 
patient at regular intervals throughout their life.198 
A fruitful and comprehensive risk assessment will generate a risk score by taking into 
account all of a patient’s risk factors. Algorithms that compute these scores will have to rely on 
the accurate collection of data. Physicians may utilize risk models such as BRCAPRO, Tyrer-
Cuzick, and Claus or the Breast Cancer Surveillance Consortium (BCSC) risk calculator which 
estimates risk in the upcoming five to ten years. Some of these instruments are more accessible 
than others; the National Cancer Institute’s Breast Cancer Risk Assessment Tool 
(https://www.cancer.gov/bcrisktool/) and the BCSC’s Risk Calculator (https://tools.bcsc-
scc.org/bc5yearrisk/calculator.htm) are available with ease via the internet. Yet, only the BCSC’s 
Risk Calculator takes into account breast density.196 In terms of the organizational processes 
involved, health care professionals will need to be periodically trained on how to utilize risk 
models. This is especially pressing given the scientific community’s inclination towards 
continually churning out new information on the genetic and environmental risks behind breast 
cancer.196 
After extrapolating information from risk tools, providers should engage patients in 
shared decision-making (SDM) to elicit their views and preferences regarding different options 
for their healthcare. It’s worth noting that in discussing the role of the clinician in this process, 
this may refer to any health professional at the imaging center or a trusted provider outside of 
this domain who can help patients deliberate their options. To facilitate this interaction, providers 
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are encouraged to follow a model based on “choice, option and decision talk: a) introducing 
choice, b) describing options, often by integrating the use of patient decision support, and c) 
helping patients explore preferences and make decisions.”200 While providers may suggest 
alternative screening pathways for patients who present unique risk factors, it is crucial that they 
thoroughly engage patients in a discussion of the benefits and harms of screening. This enables 
patients to develop informed personal preferences, while also giving them the space to articulate 
their concerns regarding screening. While providers may be challenged to pursue SDM with 
patients with low health literacy or low numeracy, by exercising good clinical communication 
skills, providers can build rapport with patients from all walks of life. This process is particularly 
important in supporting vulnerable populations who’ve been historically neglected in the 
healthcare system. The structural forces that have undermined their efforts to adhere to screening 
or routine medical care have similarly dissolved their chance to obtain personalized care. SDM 
preserves the autonomy of patients who have felt marginalized, honoring their ability to follow a 
self-determined course of action for achieving their personal wellness goals.200 
 
Delivery of Screening & Prevention Education 
 
Stratified prevention hinges on the application of risk-based screening coupled with 
general advice on modifiable lifestyle factors. Differential interventions for high and low risk 
individuals consider the risks and benefits of the use of certain screening modalities and the 
frequency of imaging. The pros and cons not only consider implications to the individual’s 
general health but also expenditures as a measure of total health care spending. Consequently, 
individuals who are at higher risk may be offered a longer period of lifetime screening while 
low-risk individuals may delay their start date for screening until they reach a later age. 
Healthcare professionals whether a technician, radiologist or primary care physician, should 
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offer consultations regarding preventative management through chemoprophylaxis or lifestyle 
habits.  
Patients may be offered the option to use alternative or adjunct screening modalities in 
addition to mammography. Advanced units like contrast enhanced mammography and digital 
breast tomosynthesis are being designed to eliminate the downsides of standard mammography.  
Contrast enhanced mammography can evaluate blood flow in breast masses similar to MRI, 
improving reader sensitivity and performance when compared with standard mammography and 
ultrasound.201 This technology requires injection of iodinated contrast. An FDA approved 
version in the U.S. was made in 2011. Digital breast tomosynthesis or 3D mammography has 
been designed to better visualize overlapping breast tissue and accordingly, decrease the rate of 
false positive and false negative findings. This is ideal for women with dense breast tissue as it 
allows the radiologist to visualize small breast cancers. During mammography, the breast is 
compressed which may cause tissue in the upper and lower breast to overlap. This would create a 
misleading appearance of cancer.202 3D mammography avoids this issue by passing X-rays 
through the breast at different angles, acquiring “slices” of the breast. Relative to standard 
mammography, digital breast tomosynthesis exposes a breast to on average 8% higher MGD per 
acquisition.203 Another limitation of tomosynthesis is a decreased sensitivity for detection of 
microcalcifications. Tomosynthesis is currently FDA approved as strictly a supplement to 
standard mammography.7 
Automated Whole-Breast Ultrasound System (AWBUS) Sonography is used as a follow-
up to ultrasound or for high-risk women or women avoiding exposure to ionizing radiation. It is 
generally accessible, incurs minimal costs, and does not utilize contrast like MRI. Hand held 
screening breast ultrasound has demonstrated significant benefits in helping radiologists acquire 
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enhanced visualization of breast tissue. A study published in the Journal of the American 
Medical Association reported a 5% chance of a biopsy being performed following ultrasound. 
The positive predictive value (PPV) which indicates the proportion of women who truly are 
diagnosed was 11%.20 On the downside, the quality of the captured image is heavily reliant on 
the technologist’s skill and experience. This poses difficulty in standardizing ultrasound 
examinations. Two-dimensional AWBUS purports to find a solution by producing consistently 
high-quality examinations through robotic machinery. A standard ultrasound probe is guided 
over both breasts through automation.204 It detects cancer at the same rate as standard ultrasound 
but has a higher PPV of 38%.205  
Computer-aided detection (CAD) systems were introduced to reduce the rate of missing 
and incorrectly interpreting visible lesions at digital mammography. These errors contribute to at 
least 25% of detectable cancers that are missed due to poor human detection performance.206–208 
Some studies assert that the use of CAD will eliminate the demand for double reading.209–212 
Many European countries employ this dual scheme of interpreting mammograms which has 
shown greater success in the number of cancers detected relative to single readings.213–218 Yet, it 
has also reportedly resulted in the recall of more women215,217–220 and use of greater resources.221 
The use of double reading of examinations may create a heavier workload for all radiologists and 
threaten their productivity.222 In the United States, mammograms are regularly interpreted by a 
single reader accompanied by computer-aided detection. Few studies have highlighted its benefit 
over single reading alone due to the low specificity of most traditional CAD systems. 
Artificial intelligence (AI) is the newest undertaking of the digital imaging market and 
has shown promise for aiding radiologists in cancer detection without requiring additional 
reading time.223 A new generation of artificial intelligence systems which are deep learning-
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based CAD systems improve both diagnostic performance and efficiency.223 A systematic review 
of the implications of AI shows that there is a general consensus of its potential to improve 
“diagnosis, clinical decision making, patient outcomes, and workflow areas in breast 
imaging.”224 Human interactions with computer behavior are still a necessary element of the 
clinical decision-making process, submitting AI to the jurisdiction and management of the 
interpreting radiologist. The physician is appointed to oversee any interpretative error made by 
the AI before it can result in an unsafe medical recommendation for the patient. Errors may 
originate in mistakes in the patient’s clinical history or poor image quality. Hence, success of AI 
has been mainly concentrated among task-based activities rather than decision-making.225 
Generally, studies report that it has improved the workflow of radiologists and increased 
accuracy in diagnosis. Future directions in breast imaging AI include developing advanced 
algorithms that account for the variables inherent to human behavior such as “human touch, the 
physician-patient relationship, and accumulated medical knowledge and experience.”224 Until 
then, AI may be most appropriately used as an adjunct to radiologist interpretation of imaging 
studies.225  
 
Communication of Results & Follow-Up 
 
Microsystems should develop formal methods for communicating results and coordinating 
follow-up for those with abnormal test results.198 Patients should be consulted before-hand to 
determine how they’d prefer to be communicated their test results, as well as relayed periodic 
reminders about their upcoming screening appointments. Individuals who’ve obtained abnormal 
mammogram results may be asked to return for follow-tests which may begin with less invasive 
tests like a diagnostic mammogram or breast ultrasound. In some instances, additional tests such 
as breast MRI or biopsy may be recommended.226  
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Leveraging professional relationships within the clinical team will help yield successful 
results in coordinating a patient’s care across multiple settings. Microsystem service and support 
staff should collectively approach this situation with compassion, helping patients alleviate 
cognitive stress related to their test results. Healthcare professionals should thoroughly inform 
diagnosed patients of the different characteristics of their cancer and management relevant to its 
severity. They may also refer them to appropriate specialists. The collective and deliberate 
efforts of the microsystem and its affiliated multidisciplinary team will ultimately help these 
patients transition across the continuum of care.  
 
Concluding Thoughts 
 
 The first step in implementing a risk-based breast cancer screening prevention program is 
galvanizing the individuals who operate within the breast center into action. Innovation should 
be made at the frontlines of healthcare by workers who are observing the challenges of 
healthcare delivery head-on. To advance this mission, organizations should operate in a way that 
provides microsystems with the resources and support to take on clinical redesign. Microsystem 
service and support staff should also situate patients at the center of innovation. By using patient 
safety and autonomy as a driving force towards quality improvement, they can move closer 
towards achieving “improved care, continuity, communication and coordination, and cultural 
competency.”227  
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